FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2535894966> ?p ?o ?g. }

• W2535894966 endingPage "25678" @default.
• W2535894966 startingPage "25669" @default.
• W2535894966 abstract "// Jie Li 1,* , Ming Lu 1,* , Zhihao Lu 1,* , Zhongwu Li 2 , Yiqiang Liu 2 , Li Yang 3 , Jian Li 1 , Xiaotian Zhang 1 , Jun Zhou 1 , Xicheng Wang 1 , Jifang Gong 1 , Jing Gao 1 , Yan Li 1 and Lin Shen 1 1 Department of GI Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China 2 Department of Pathology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China 3 Center of clinical oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China * These authors have contributed equally to this work Correspondence to: Lin Shen, email: // Keywords : gastroenteropancreatic neuroendocrine carcinomas; irinotecan; cisplatin; octreotide long-acting release; heterogeneous Received : February 21, 2016 Accepted : October 16, 2016 Published : October 25, 2016 Abstract There have been very few prospective studies of first-line chemotherapy on advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). This phase II study assessed the activity and safety of irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment in advanced GEP-NEC. Forty patients were treated and eighteen patients (45.0%) had a partial response. The median progression-free survival (PFS) and overall survival (OS) were 5.7 months and 12.9 months, respectively. Because GEP-NECs are heterogeneous, a subgroup analysis was conducted by dividing all patients into a high proliferation neuroendocrine tumor (NET) group (well differentiated neuroendocrine neoplasms with a Ki-67 level between 20-60%) or a poorly differentiated NEC (PDNEC) group. Compared with the PDNEC group, the patients in high proliferation NET group had a lower response rate (0% versus 51.4%) but longer PFS (8.9 versus 5.7 months) and received more octreotide LAR treatment (median cycles, 7 versus 3). The most common toxicities included grade 3/4 leukopenia/neutropenia (60%), nausea/vomiting (17.5%) and diarrhea (12.5%). Therefore, IP is an active regimen in patients with advanced GEP-PDNEC and should probably not be given to patients with advanced high proliferative NET. The benefit of octreotide LAR maintenance therapy on high proliferation NETs requires further study." @default.
• W2535894966 created "2016-10-28" @default.
• W2535894966 creator A5006511913 @default.
• W2535894966 creator A5025401873 @default.
• W2535894966 creator A5026373258 @default.
• W2535894966 creator A5026847991 @default.
• W2535894966 creator A5034342116 @default.
• W2535894966 creator A5035364200 @default.
• W2535894966 creator A5035535613 @default.
• W2535894966 creator A5046118596 @default.
• W2535894966 creator A5052883326 @default.
• W2535894966 creator A5059392900 @default.
• W2535894966 creator A5072537482 @default.
• W2535894966 creator A5073995543 @default.
• W2535894966 creator A5084407437 @default.
• W2535894966 creator A5086753069 @default.
• W2535894966 date "2016-10-25" @default.
• W2535894966 modified "2023-09-22" @default.
• W2535894966 title "Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study" @default.
• W2535894966 cites W1555094309 @default.
• W2535894966 cites W1967988142 @default.
• W2535894966 cites W1989736194 @default.
• W2535894966 cites W1995681258 @default.
• W2535894966 cites W2004291258 @default.
• W2535894966 cites W2022243114 @default.
• W2535894966 cites W2027170387 @default.
• W2535894966 cites W2044561683 @default.
• W2535894966 cites W2047020361 @default.
• W2535894966 cites W2062907835 @default.
• W2535894966 cites W2073683299 @default.
• W2535894966 cites W2081019043 @default.
• W2535894966 cites W2081170063 @default.
• W2535894966 cites W2081457024 @default.
• W2535894966 cites W2081844536 @default.
• W2535894966 cites W2094551615 @default.
• W2535894966 cites W2123060958 @default.
• W2535894966 cites W2123965872 @default.
• W2535894966 cites W2129462305 @default.
• W2535894966 cites W2135049144 @default.
• W2535894966 cites W2137142564 @default.
• W2535894966 cites W2149214723 @default.
• W2535894966 cites W2152688862 @default.
• W2535894966 cites W2158604085 @default.
• W2535894966 cites W2161676563 @default.
• W2535894966 cites W2162011212 @default.
• W2535894966 cites W2165062498 @default.
• W2535894966 cites W2172114131 @default.
• W2535894966 cites W4299526958 @default.
• W2535894966 doi "https://doi.org/10.18632/oncotarget.12900" @default.
• W2535894966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5421960" @default.
• W2535894966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27788498" @default.
• W2535894966 hasPublicationYear "2016" @default.
• W2535894966 type Work @default.
• W2535894966 sameAs 2535894966 @default.
• W2535894966 citedByCount "8" @default.
• W2535894966 countsByYear W25358949662018 @default.
• W2535894966 countsByYear W25358949662019 @default.
• W2535894966 countsByYear W25358949662020 @default.
• W2535894966 countsByYear W25358949662021 @default.
• W2535894966 countsByYear W25358949662023 @default.
• W2535894966 crossrefType "journal-article" @default.
• W2535894966 hasAuthorship W2535894966A5006511913 @default.
• W2535894966 hasAuthorship W2535894966A5025401873 @default.
• W2535894966 hasAuthorship W2535894966A5026373258 @default.
• W2535894966 hasAuthorship W2535894966A5026847991 @default.
• W2535894966 hasAuthorship W2535894966A5034342116 @default.
• W2535894966 hasAuthorship W2535894966A5035364200 @default.
• W2535894966 hasAuthorship W2535894966A5035535613 @default.
• W2535894966 hasAuthorship W2535894966A5046118596 @default.
• W2535894966 hasAuthorship W2535894966A5052883326 @default.
• W2535894966 hasAuthorship W2535894966A5059392900 @default.
• W2535894966 hasAuthorship W2535894966A5072537482 @default.
• W2535894966 hasAuthorship W2535894966A5073995543 @default.
• W2535894966 hasAuthorship W2535894966A5084407437 @default.
• W2535894966 hasAuthorship W2535894966A5086753069 @default.
• W2535894966 hasBestOaLocation W25358949661 @default.
• W2535894966 hasConcept C121608353 @default.
• W2535894966 hasConcept C126322002 @default.
• W2535894966 hasConcept C143998085 @default.
• W2535894966 hasConcept C204232928 @default.
• W2535894966 hasConcept C2776297358 @default.
• W2535894966 hasConcept C2776694085 @default.
• W2535894966 hasConcept C2779066768 @default.
• W2535894966 hasConcept C2780259306 @default.
• W2535894966 hasConcept C2780739268 @default.
• W2535894966 hasConcept C2781025020 @default.
• W2535894966 hasConcept C526805850 @default.
• W2535894966 hasConcept C71924100 @default.
• W2535894966 hasConcept C77231918 @default.
• W2535894966 hasConcept C90924648 @default.
• W2535894966 hasConceptScore W2535894966C121608353 @default.
• W2535894966 hasConceptScore W2535894966C126322002 @default.
• W2535894966 hasConceptScore W2535894966C143998085 @default.
• W2535894966 hasConceptScore W2535894966C204232928 @default.
• W2535894966 hasConceptScore W2535894966C2776297358 @default.
• W2535894966 hasConceptScore W2535894966C2776694085 @default.
• W2535894966 hasConceptScore W2535894966C2779066768 @default.
• W2535894966 hasConceptScore W2535894966C2780259306 @default.

• next